Survival analysis
| Variable | Univariable HR (95% CI) | p Value | Multivariable HR (95% CI) (missing N=13)* | p Value |
|---|---|---|---|---|
| Effusion mesothelin† | 0.82 (0.53 to 1.27) | 0.365 | 1.09 (0.55 to 2.17) | 0.794 |
| Plasma mesothelin† | 0.89 (0.55 to 1.40) | 0.585 | 0.60 (0.32 to 1.22) | 0.164 |
| Effusion fibulin-3† | 2.32 (1.42 to 3.79) | 0.001 | 2.08 (1.14 to 3.82) | 0.017 |
| Plasma fibulin-3† | 1.23 (0.49 to 3.10) | 0.655 | 3.47 (0.78 to 15.42) | 0.103 |
| Age‡ | 1.05 (1.02 to 1.08) | 0.002 | 1.05 (0.99 to 1.01) | 0.062 |
| Sex | ||||
| Female | Ref | |||
| Male | 1.50 (0.65 to 3.47) | 0.340 | 0.87 (0.31 to 2.42) | 0.785 |
| Histology | ||||
| Epitheliod | Ref | |||
| Not specified | 0.98 (0.55 to 1.76) | 0.950 | 1.38 (0.64 to 2.98) | 0.361 |
| Biphasic or sarcomatoid | 2.76 (1.47 to 5.21) | 0.002 | 2.81 (1.32 to 6.00) | 0.008 |
| ECOG PS (missing N=5)* | ||||
| 0–1 | Ref | |||
| 2–3 | 3.36 (1.79 to 6.29) | <0.001 | 2.27 (0.83 to 6.2) | 0.110 |
| Stage (missing N=7)* | ||||
| I–II | Ref | |||
| III–IV | 1.22 (0.73 to 2.03) | 0.449 | 1.23 (0.65 to 2.33) | 0.520 |
| Weight loss (missing N=5)* | ||||
| Absent | Ref | |||
| Present | 1.48 (0.91 to 2.42) | 0.116 | 0.54 (0.27 to 1.08) | 0.083 |
| Chest pain (missing N=5)* | ||||
| Absent | Ref | |||
| Present | 1.67 (0.99 to 2.80) | 0.054 | 1.92 (0.93 to 3.98) | 0.080 |
| Hb difference§ (missing N=2)* | ||||
| <10 g/L | Ref | |||
| ≥10 g/L | 1.99 (1.15 to 3.45) | 0.014 | 1.35 (0.65 to 2.82) | 0.418 |
| White cell count (missing N=2)* | ||||
| ≤8.3×109/L | Ref | |||
| >8.3×109/L | 1.36 (0.843 to 2.19) | 0.208 | 1.37 (0.69 to 2.74) | 0.372 |
| Platelet count (missing N=2)* | ||||
| ≤400×109/L | Ref | |||
| >400×109/L | 1.73 (1.03 to 2.92) | 0.039 | 1.54 (0.74 to 2.74) | 0.246 |
| NLR (missing N=2)* | ||||
| <5 | Ref | |||
| ≥5 | 1.31 (0.78 to 2.22) | 0.306 | 1.29 (0.65 to 2.56) | 0.460 |
| Treatment (missing N=4)* | ||||
| Best supportive care | Ref | Not included | ||
| Active treatment | 2.82 (1.75 to 4.54) | 0.001 | ||
| EORTC group (missing N=3)* | ||||
| Low risk | Ref | Not included | ||
| High risk | 1.32 (0.82 to 2.13) | 0.256 | ||
| CALGB group (missing N=7)* | ||||
| 1 or 2 | Ref | Not included | ||
| 3 or 4 | 1.36 (0.72 to 2.60) | 0.346 | ||
| 5 or 6 | 2.78 (1.41 to 5.50) | 0.004 | ||
Entries in bold type are statistically significant.
Cox regression analysis of MM survival.
*Number of cases with missing data.
†HRs for biomarkers is for a log(10) unit increase.
‡HR for age is for a 1 year increase.
§Hb, haemoglobin expressed as a difference relative to 160 g/L in men and 140 g/L in women.
CALGB, Cancer and Leukaemia Group B; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EORTC, European Organisation for Research and Treatment of Cancer; MM, malignant mesothelioma; NLR, neutrophil to lymphocyte ratio.